Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00790855 · ClinicalTrials.gov registry record · Phase 1

Bendamustine in Acute Leukemia and MDS

A Phase 1 study, sponsored by M.D. Anderson Cancer Center.

Terminated
Registry status
Phase 1
Development phase
27
Enrollment target

NCT00790855: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.

NCT00790855 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00790855, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.

TERMINATED
Registry status
Phase 1
Development phase
27 participants
Enrollment target

Study Summary

The goal of the Phase I part of this clinical research study is to find the highest safe dose of bendamustine that can be given to patients with acute myelogenous leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myelogenous (or myeloid) leukemia (CML) in blastic phase, Chronic Myelomonocytic Leukemia (CMML), and myelodysplastic syndromes (MDS). The goal of the Phase II part of this clinical research study is to learn if bendamustine can help to control AML, ALL and MDS. The safety of this drug will continue to be studied.

Primary Outcome

The MTD is the highest dose level in which \<2 patients of 6 develop first cycle dose limiting toxicity (DLT). MTD assessed during course 1 (4 week cycle), every 3-7 days.

Interventions

  • DRUG Bendamustine

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2008-11
Est. Completion 2012-03
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

Why NCT00790855 stopped before completion

NCT00790855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 1 intervention - of which Bendamustine is the first listed.

NCT00790855 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00790855 about?

NCT00790855 is a clinical study titled "Bendamustine in Acute Leukemia and MDS". The goal of the Phase I part of this clinical research study is to find the highest safe dose of bendamustine that can be given to patients with acute myelogenous leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myelogenous (or myeloid) leukemia (CML) in blastic phase, Chronic Myelomonocy...

What is the current status of trial NCT00790855?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-11. Estimated completion is 2012-03.

What interventions are being tested in trial NCT00790855?

The interventions under investigation include: Bendamustine (DRUG).

Who is sponsoring clinical trial NCT00790855?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00790855's enrollment target sits among peer trials

27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00790855, the US trial registry maintained by the National Library of Medicine. NCT00790855 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.